1369880-56-7Relevant academic research and scientific papers
Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold
Wender, Paul A.,Staveness, Daryl
, p. 5140 - 5143 (2014)
Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer's disease, and a first-of-its-kind strategy for HIV/AIDS eradication, is neither readily available nor optimally suited for clinical use. In preceding work, we disclosed a new class of simplified bryostatin analogs designed for ease of access and tunable activity. Here we describe a final step diversification strategy that provides, in only 25 synthetic steps, simplified and tunable analogs with bryostatin-like PKC modulatory activities.
Pd(II)-catalyzed bromo- and chlorodecarboxylation of electron-rich arenecarboxylic acids
Peng, Xuefeng,Shao, Xiang-Feng,Liu, Zhong-Quan
supporting information, p. 3079 - 3081 (2013/07/11)
A bromo- and chlorodecarboxylation of various aromatic carboxylic acids catalyzed by Pd(II) has been developed in this work. A series of electron-rich arenecarboxylic acids gave the corresponding decarboxylative monohalogenation products under the typical reaction conditions.
